



## Intron® A (interferon alfa-2b) – Product discontinuation

- Merck announced the permanent discontinuation of Intron A (interferon alfa-2b).
  - Intron A is being discontinued due to business reasons and is not due to any safety, efficacy or quality reasons.
  - Intron A powder for injection is expected to be discontinued on or near March 2022.
  - Intron A solution for injection was discontinued June 2021 - July 2021.
  - There are no other manufacturers that produce interferon alfa-2b.
- Intron A is indicated for the treatment of hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata, AIDS-related Kaposi's sarcoma, chronic hepatitis C, and chronic hepatitis B.
- Alternatives to Intron A are available and choice of therapy depends upon the indication with which Intron A is being used for.
- Patients currently using Intron A should consult with their healthcare provider for guidance on other available treatments.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.